Open Targets Platform API
Open Targets Platform API
Open Targets (platform.opentargets.org) provides a keyless GraphQL API for target-disease association evidence (genetic associations, known drugs, pathways, RNA/protein expression, literature) aggregated from partner data sources by EMBL-EBI, GSK and Wellcome Sanger. A live meta query confirms the API names itself "Open Targets GraphQL & REST API Beta".
Required Attribution:
Not required (CC0).
Coverage
Target-disease association evidence (genetics, known drugs, pathways, RNA/protein expression, literature) built from partner data sources, confirmed live today via a GraphQL meta query (data version 26.09). History start and update frequency: Not stated.
Verdict
Keyless GraphQL API for target-disease association evidence (genetics, known drugs, pathways, expression, literature) from Open Targets, which names itself "Open Targets GraphQL & REST API Beta" live. Licensed CC0-1.0: "Open Targets Platform is marked with CC0 1.0 . This dedicates the data to the public domain, allowing downstream users to consume the data without restriction." The licence page adds: "Please note that all data sources listed in the table, including the ones labeled with 'commercial use for Open Targets', have agreed for their data to be used without restriction by all Open Targets users." Rate limits: Not stated. Signal Lab links only.
Get the free weekly email
Free weekly email of newly verified free data. Unsubscribe by emailing us.
By entering your email and clicking Subscribe, you agree to receive the Signal Lab weekly email from Quantum Data Technologies Ltd., 3200-650 West Georgia Street, Vancouver, BC V6B 4P7, Canada (signal-lab@qdt.ai). You can unsubscribe at any time: reply "unsubscribe" to any email or write to signal-lab@qdt.ai. See our Privacy Policy.
Information and education only. Not financial, investment, legal or tax advice. Listings can be inaccurate, incomplete or out of date and are provided "as is". Free tiers, limits and licenses belong to each provider and can change, so check the provider's own terms before you rely on them. Terms & Disclaimer